Diseases of the Breast

Por Coleman, RE
Publicado em 1997

Targeting the tumour microenvironment: denosumab, a new RANKL inhibitor

Por Coleman, RE
Publicado no Breast Cancer Res (2009)

Benefits of combined treatments using antiresorptive agents and cytotoxic drugs

Por Holen, I, Neville-Webbe, H, Coleman, RE
Publicado em 2006

Synergistic effects of cytotoxic drugs and antiresorptive agents in vitro and in vivo

Por Ottewell, PD, Jones, M, Coleman, RE, Holen, I
Publicado em 2006

Effects of combined treatment with Zometa and Taxol on endothelial cells in vitro

Por Michailidou, M, Brown, N, Coleman, RE, Holen, I
Publicado em 2006

Pretreatment of breast cancer cells with doxorubicin facilitates the subsequent uptake of zoledronic acid

Por Lefley, DV, Holen, I, Coleman, RE, Ottewell, PD
Publicado em 2008

Mechanisms of apoptosis and cell-cycle arrest in subcutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid

Por Ottewell, PD, Lefley, DV, Coleman, RE, Holen, I
Publicado em 2008

A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts

Por Brown, H.K., Ottewell, P.D., Evans, C.A., Coleman, R.E., Holen, I.
Publicado no J Bone Oncol (2012)

The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer

Por Anderson, R.A., Mansi, J., Coleman, R.E., Adamson, D.J.A., Leonard, R.C.F.
Publicado no Eur J Cancer (2017)

Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma

Por Palmer, J, Goggins, T, Broadwater, G, Chao, N, Horwitz, M, Beaven, A, Sullivan, K, Coleman, RE, Rizzieri, D
Publicado em 2010

Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial

Por Lester, J.E., Dodwell, D., Brown, J.E., Purohit, O.P., Gutcher, S.A., Ellis, S.P., Thorpe, R., Horsman, J.M., Coleman, R.E.
Publicado no J Bone Oncol (2012)

Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials

Por Kroep, J.R., Charehbili, A., Coleman, R.E., Aft, R.L., Hasegawa, Y., Winter, M.C., Weilbaecher, K., Akazawa, K., Hinsley, S., Putter, H., Liefers, G.J., Nortier, J.W.R., Kohno, N.
Publicado no Eur J Cancer (2015)

Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging

Por Johnson, KA, Sperling, RA, Gidicsin, C, Carmasin, J, Maye, J, Coleman, RE, Reiman, EM, Sabbagh, MN, Sadowsky, CH, Fleisher, AS, Doraiswamy, PM, Carpenter, AP, Clark, CM, Joshi, AD, Lu, M, Grundman, M, Mintun, MA, Pontecorvo, MJ, Skovronsky, DM
Publicado em 2013

Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)

Por Coleman, R.E., Collinson, M., Gregory, W., Marshall, H., Bell, R., Dodwell, D., Keane, M., Gil, M., Barrett-Lee, P., Ritchie, D., Bowman, A., Liversedge, V., De Boer, R.H., Passos-Coelho, J.L., O'Reilly, S., Bertelli, G., Joffe, J., Brown, J.E., Wilson, C., Tercero, J.C., Jean-Mairet, J., Gomis, R., Cameron, D.
Publicado no J Bone Oncol (2018)